Literature DB >> 23296926

HPLC purification of in vitro transcribed long RNA.

Drew Weissman1, Norbert Pardi, Hiro Muramatsu, Katalin Karikó.   

Abstract

In vitro transcription of DNA with phage RNA polymerases is currently the most efficient method to produce long sequence-specific RNA. While the reaction can yield large quantities of RNA, it contains impurities due to various unwanted activities of the polymerases. Here, we described an easily performed HPLC purification that removes multiple contaminants from in vitro transcribed RNA and is scalable. The purified RNA is translated at much greater levels, especially in primary cells and in vivo. HPLC purification of RNA containing modified nucleosides that suppress RNA-mediated activation of innate immune sensors leads to a non-immunogenic RNA with superior translational capacity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23296926     DOI: 10.1007/978-1-62703-260-5_3

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  54 in total

Review 1.  mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.

Authors:  Giulietta Maruggi; Cuiling Zhang; Junwei Li; Jeffrey B Ulmer; Dong Yu
Journal:  Mol Ther       Date:  2019-02-07       Impact factor: 11.454

Review 2.  Vaccines to prevent genital herpes.

Authors:  Kevin Egan; Lauren M Hook; Philip LaTourette; Angela Desmond; Sita Awasthi; Harvey M Friedman
Journal:  Transl Res       Date:  2020-03-16       Impact factor: 7.012

Review 3.  mRNA vaccines - a new era in vaccinology.

Authors:  Norbert Pardi; Michael J Hogan; Frederick W Porter; Drew Weissman
Journal:  Nat Rev Drug Discov       Date:  2018-01-12       Impact factor: 84.694

4.  Formulation and Delivery Technologies for mRNA Vaccines.

Authors:  Chunxi Zeng; Chengxiang Zhang; Patrick G Walker; Yizhou Dong
Journal:  Curr Top Microbiol Immunol       Date:  2020-06-02       Impact factor: 4.291

5.  Nucleoside-modified mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in mice.

Authors:  Elinor Willis; Norbert Pardi; Kaela Parkhouse; Barbara L Mui; Ying K Tam; Drew Weissman; Scott E Hensley
Journal:  Sci Transl Med       Date:  2020-01-08       Impact factor: 17.956

6.  Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization.

Authors:  Cody S Nelson; Jennifer A Jenks; Norbert Pardi; Matthew Goodwin; Hunter Roark; Whitney Edwards; Jason S McLellan; Justin Pollara; Drew Weissman; Sallie R Permar
Journal:  J Virol       Date:  2020-04-16       Impact factor: 5.103

7.  Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes.

Authors:  Sita Awasthi; Lauren M Hook; Norbert Pardi; Fushan Wang; Arpita Myles; Michael P Cancro; Gary H Cohen; Drew Weissman; Harvey M Friedman
Journal:  Sci Immunol       Date:  2019-09-20

8.  Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes.

Authors:  Norbert Pardi; Steven Tuyishime; Hiromi Muramatsu; Katalin Kariko; Barbara L Mui; Ying K Tam; Thomas D Madden; Michael J Hope; Drew Weissman
Journal:  J Control Release       Date:  2015-08-08       Impact factor: 9.776

9.  Evaluation of a Single-Dose Nucleoside-Modified Messenger RNA Vaccine Encoding Hendra Virus-Soluble Glycoprotein Against Lethal Nipah virus Challenge in Syrian Hamsters.

Authors:  Michael K Lo; Jessica R Spengler; Stephen R Welch; Jessica R Harmon; JoAnn D Coleman-McCray; Florine E M Scholte; Punya Shrivastava-Ranjan; Joel M Montgomery; Stuart T Nichol; Drew Weissman; Christina F Spiropoulou
Journal:  J Infect Dis       Date:  2020-05-11       Impact factor: 5.226

10.  Modulation of mRNA Translation and Cell Viability by Influenza A Virus Derived Nonstructural Protein 1.

Authors:  Yi Liu; Zhen Hua Chia; Johannes Nathaniel Min Hui Liew; Shi Min Or; Kyle K L Phua
Journal:  Nucleic Acid Ther       Date:  2018-04-10       Impact factor: 5.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.